<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04117932</url>
  </required_header>
  <id_info>
    <org_study_id>PO19083</org_study_id>
    <nct_id>NCT04117932</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ustekinumab in Bullous Pemphigoid</brief_title>
  <acronym>PB-USTE</acronym>
  <official_title>Efficacy and Safety of Ustekinumab in Bullous Pemphigoid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease and typically&#xD;
      affects the elderly. Clinically, BP is an intensely pruritic erythematous eruption with&#xD;
      widespread blister formation. BP is usually a chronic disease, with spontaneous exacerbations&#xD;
      and remissions, which may be accompanied by significant morbidity.&#xD;
&#xD;
      BP usually requires on average a 1-year duration of treatment. Superpotent topical&#xD;
      corticosteroids have been demonstrated to be effective. Despite their high efficacy, topical&#xD;
      corticosteroids are often considered as poorly convenient, requiring the assistance of&#xD;
      patients' relatives or a nurse to apply the topical treatment on a long period of time.&#xD;
&#xD;
      Overall, whereas BP lesions can be adequately and rapidly controlled with either topical&#xD;
      corticosteroids, there is a high need for a safe maintenance therapy to avoid treatment side&#xD;
      effects due to cumulative doses of corticosteroids over months.&#xD;
&#xD;
      Newer therapeutic agents such as ustekinumab targeting molecules involved in the inflammatory&#xD;
      cascade associated with BP represent future alternatives to classical immunosuppressant drugs&#xD;
      for maintenance therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to evaluate efficacy of ustekinumab in association during 8 weeks&#xD;
      with superpotent topical corticosteroids in patients with bullous pemphigoid&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2020</start_date>
  <completion_date type="Anticipated">April 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 11, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete remission</measure>
    <time_frame>28 weeks</time_frame>
    <description>Complete remission is defined as the absence of new or established lesions (bullae, eczematous lesions or urticarial lesions)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Bullous Pemphigoid</condition>
  <arm_group>
    <arm_group_label>Arm &quot;ustekinumab&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with bullous pemphigoid, treated using ustekinumab in association during 8 weeks with superpotent topical corticosteroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>Ustekinumab (90 mg subcutaneously at weeks 0, 4, 16), in association with topical superpotent corticosteroid (10-30 g per day during the first 4 weeks, then every other day during 4 weeks).</description>
    <arm_group_label>Arm &quot;ustekinumab&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        inclusion criteria :&#xD;
&#xD;
          -  patient with bullous pemphigoid&#xD;
&#xD;
          -  patient aged between 18 and 90&#xD;
&#xD;
          -  patient with Karnofsky Performance score &gt; 60%&#xD;
&#xD;
          -  patient agreed to participate to the study&#xD;
&#xD;
        exclusion criteria :&#xD;
&#xD;
          -  patient with allergy to corticosteroids&#xD;
&#xD;
          -  patient with allergy to ustekinumab&#xD;
&#xD;
          -  patient with any severe medical condition at time of inclusion including stroke, heart&#xD;
             failure, renal failure, high blood pressure and diabetes mellitus&#xD;
&#xD;
          -  malignancy &lt; 5 years prior to inclusion&#xD;
&#xD;
          -  pregnant or nursing (lactating) women, or women of child-bearing potential&#xD;
&#xD;
          -  active infection or with recent history of clinically significant infection within 4&#xD;
             weeks prior to inclusion&#xD;
&#xD;
          -  history or presence of infection with hepatitis B or C.&#xD;
&#xD;
          -  history or presence of immunodeficiency diseases, including a positive HIV (ELISA and&#xD;
             Western blot) test result.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Manuelle VIGUIER</last_name>
    <phone>03 10 73 66 76</phone>
    <email>mviguier@chu-reims.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Damien JOLLY</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuelle VIGUIER</last_name>
      <phone>03 10 73 66 76</phone>
      <phone_ext>0033</phone_ext>
      <email>mviguier@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 4, 2019</study_first_submitted>
  <study_first_submitted_qc>October 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bullous pemphigoid</keyword>
  <keyword>ustekinumab</keyword>
  <keyword>superpotent topical corticosteroids</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigoid, Bullous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

